Online citations, reference lists, and bibliographies.

Aliskiren (Tekturna), The First‐in‐Class Renin Inhibitor For Hypertension

V. Cee
Published 2010 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
This paper references
10.2165/00003088-200847080-00002
Clinical Pharmacokinetics and Pharmacodynamics of Aliskiren
S. Vaidyanathan (2008)
10.1016/S0040-4039(00)01794-9
A convergent synthesis approach towards CGP60536B, a non-peptide orally potent renin inhibitor, via an enantiomerically pure ketolactone intermediate
H. Rueeger (2000)
10.1038/303081a0
Novel renin inhibitors containing the amino acid statine
J. Boger (1983)
10.1097/00004872-200311000-00002
2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension
J. Whitworth (2003)
10.1021/JM070314Y
Novel 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamide transition state peptidomimetics are potent and orally active inhibitors of human renin.
Richard Göschke (2007)
10.1016/S1359-6446(05)03488-4
Alice Huxley and Nick Miles of Speedel on the company's pipeline and future plans. Interview by Christopher Watson and Stephen Carney.
A. Huxley (2005)
10.1038/299555a0
Potent new inhibitors of human renin
M. Szelke (1982)
10.1161/HY0102.102293
Angiotensin II Suppression in Humans by the Orally Active Renin Inhibitor Aliskiren (SPP100): Comparison With Enalapril
J. Nussberger (2002)
10.1021/jo00225a040
Stereocontrolled synthesis of a polyether fragment
P. Bartlett (1985)
10.1016/S0960-894X(01)81029-5
Peptidomimetic inhibitors of renin incorporating topographically modified isosteres spanning the P1(→P3)-P1' sites
M. Plummer (1993)
10.1177/1470320309104662
Managing cardiovascular and renal risk: the potential of direct renin inhibition
P. Sever (2009)
10.1002/HLCA.200390235
The Nonchiral Bislactim Diethoxy Ether as a Highly Stereo‐Inducing Synthon for Sterically Hindered, γ‐Branched α‐Amino Acids: A Practical, Large‐Scale Route to an Intermediate of the Novel Renin Inhibitor Aliskiren
Richard Goschke (2003)
10.1016/S0960-894X(00)80364-9
Design and synthesis of a prototypical non-peptidic inhibitor model for the enzme renin
S. Hanessian (1994)
10.1016/S1074-5521(00)00134-4
Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin.
J. Rahuel (2000)
10.1016/S0960-894X(97)10067-1
Design and synthesis of novel 2,7-dialkyl substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides as in vitro potent peptidomimetic inhibitors of human renin
Richard Goschke (1997)
10.1113/JPHYSIOL.2003.049890
Renin: origin, secretion and synthesis.
P. Persson (2003)
10.1021/JM070316I
Structural modification of the P2' position of 2,7-dialkyl-substituted 5(S)-amino-4(S)-hydroxy-8-phenyl-octanecarboxamides: the discovery of aliskiren, a potent nonpeptide human renin inhibitor active after once daily dosing in marmosets.
J. Maibaum (2007)
10.1016/S0140-6736(07)61124-6
Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: a randomised, double-blind trial
S. Oparil (2007)
10.1056/NEJMoa0708379
Aliskiren combined with losartan in type 2 diabetes and nephropathy.
Hans‐Henrik Parving (2008)
10.1111/j.1748-1716.1898.tb00272.x
Niere und Kreislauf1
R. Tigerstedt (1898)
10.1161/CIRCULATIONAHA.108.826214
Effect of the Direct Renin Inhibitor Aliskiren, the Angiotensin Receptor Blocker Losartan, or Both on Left Ventricular Mass in Patients With Hypertension and Left Ventricular Hypertrophy
S. Solomon (2009)
10.1161/CIRCHEARTFAILURE.107.740704
Effects of the Oral Direct Renin Inhibitor Aliskiren in Patients With Symptomatic Heart Failure
J. McMurray (2008)
10.1021/JM00015A012
Design and synthesis of renin inhibitors: incorporation of transition-state isostere side chains that span from the S1 to the S3 binding pockets and examination of P3-modified renin inhibitors.
M. Plummer (1995)
10.1016/0960-894X(95)00456-4
Rational design, synthesis, and X-ray structure of renin inhibitors with extended P1 sidechains
B. Lefker (1995)
10.1021/ja00316a044
1,3-Asymmetric induction: highly stereoselective synthesis of 2,4-trans-disubstituted γ-butyrolactones and γ-butyrothiolactones
Y. Tamaru (1984)
10.1016/S0040-4039(00)01760-3
A convergent synthesis of the renin inhibitor CGP60536B
D. A. Sandham (2000)
10.1097/HJH.0b013e3280103a6b
Renin inhibition with aliskiren provides additive antihypertensive efficacy when used in combination with hydrochlorothiazide
A. Villamil (2007)
10.1016/S0006-291X(03)01451-7
Structure-based design of aliskiren, a novel orally effective renin inhibitor.
J. Wood (2003)
10.3317/jraas.2007.028
Efficacy and safety of the direct renin inhibitor aliskiren and ramipril alone or in combination in patients with diabetes and hypertension
Y. Uresin (2007)
10.1038/nrd873
Drugs targeting the renin–angiotensin–aldosterone system
M. A. Zaman (2002)
10.1016/S0065-7743(09)04405-4
Chapter 5 Case History on Tekturna®/Rasilez® (Aliskiren), a Highly Efficacious Direct Oral Renin Inhibitor as a New Therapy for Hypertension
J. Maibaum (2009)
10.1681/ASN.2004100874
Renin inhibition: what are the therapeutic opportunities?
N. D. Fisher (2005)
10.1038/nrd2550
Aliskiren: the first renin inhibitor for clinical treatment
C. Jensen (2008)



This paper is referenced by
Semantic Scholar Logo Some data provided by SemanticScholar